MHRA
MHRA publishes Women’s Health Programme for 2026 to 2030
The programme supports better evidence and regulation of medicines and medical devices to improve health outcomes for women.
Read the official sourceMHRA
MHRA updates its clinical trials hub
The collection brings together the UK legal framework, regulatory requirements, and guidance for designing, applying for, conducting, modifying, closing, and maintaining compliance in medicines trials.
Read the official sourceEMA
EMA opens consultation on medically important VeDDRA terms
A draft guideline on veterinary good pharmacovigilance practices and the list of medically important VeDDRA terms is open for consultation.
Read the official sourceEMA
EMA consults on revised VICH GL49
Revision 2, covering validation of analytical methods used in veterinary residue depletion studies, is available as a draft for consultation.
Read the official sourceFDA
FDA confirms effective date for Orange B listing revocation
FDA confirmed September 8, 2026, as the effective date of the final order repealing the regulation that allowed Orange B on frankfurter and sausage casings or surfaces.
Read the official sourceWhy this matters
Regulatory teams should note MHRA’s focus on evidence gaps affecting women and use the consolidated UK trial resources when navigating clinical trial requirements. The EMA consultations provide formal opportunities to comment on veterinary pharmacovigilance terminology and analytical method validation, while FDA’s notice confirms the implementation date of a completed rulemaking action.
Scott Morvay
Founder, Gulfstream Intelligence
This brief provides general regulatory news and educational information. It is not legal or regulatory advice.